Baseline Starting Dose — 75 mg Twice Daily
Low starting dose limits early sedation while therapy begins.
- 150 mg/day: Starting dose (75 mg twice daily)
- ~6.3 h: Half-life (renal clearance, linear PK)
- ≥90%: Bioavailability (not protein bound)
- ~24–48 h: Time to steady state (after each dose change)
Why start low
Low first dose reduces early dizziness and sedation risk.
Pharmacokinetics
Linear kinetics, renal excretion, minimal drug interactions.
Patient selection
Renal dose adjustment needed for reduced kidney function.
Gradual Up-Titration to Target Dose
Dose increases stepwise toward 150–225 mg twice daily.
- 300–450 mg/day: Target dose range (150–225 mg twice daily)
- 1–2 weeks: Titration window (weekly dose increments)
- 450 mg/day: Max approved dose (FDA fibromyalgia label)
- +150 mg/wk: Common increment (as tolerated)
Titration schedule
Stepwise increases allow tolerance to sedation to build.
Monitoring
Watch for dizziness, somnolence, weight gain, edema.
Discontinuation
Taper gradually over one week to avoid withdrawal.
α2δ Subunit Binding at the Nerve Terminal
Pregabalin binds voltage-gated calcium channel auxiliary subunits.
- α2δ-1 subunit: Binding target (voltage-gated Ca²⁺ channels)
- ↓ Ca²⁺ influx: Channel effect (reduced presynaptic entry)
- Glutamate, substance P: Neurotransmitters reduced (excitatory release)
- Non-opioid: Mechanism class (gabapentinoid, not GABA-mimetic)
Channel binding
Binds auxiliary subunit, not the pore-forming subunit itself.
Downstream effect
Fewer calcium ions trigger vesicle fusion and release.
Central sensitization
Dampened excitatory signaling reduces pain amplification.
Analgesic Benefit and Sedation Rise in Parallel
Higher doses bring more relief but also more sedation.
- Saturating: Relief curve shape (diminishing returns at high dose)
- Sigmoidal: Sedation curve shape (steep rise past ~400 mg/day)
- Dizziness, somnolence: Common side effects (dose-dependent incidence)
- ~15–20%: Discontinuation for AEs (clinical trial data)
Analgesia curve
Pain relief saturates as receptor occupancy approaches maximum.
Sedation curve
Sedation accelerates once dose exceeds tolerability threshold.
Divergence point
Curves separate, defining the useful therapeutic window.
Finding the Balance Point — Net Clinical Benefit
Optimal dose maximizes relief while keeping sedation tolerable.
- ~300–375 mg/day: Typical sweet spot (model-estimated peak net benefit)
- 450 mg/day: Diminishing returns above (sedation outpaces added relief)
- Titrate to effect: Individualization (balance efficacy and tolerability)
- ~40–50%: Responder rate (≥30% pain reduction, trials)
Net benefit score
Relief minus weighted sedation burden defines the optimum.
Too-high doses
Over-sedation without proportional additional pain relief.
Clinical takeaway
Titrate slowly, find each patient's individual sweet spot.
Slow titration to the lowest effective dose maximizes tolerability.